Chemical Proteomics of Residual Acute Myeloid Leukemia Cells Reveals Therapeutic Vulnerabilities
Elham Gholizadeh, Uladzislau Vadadokhau, Mücahit Varlı, Danilo Ritz, Komal Kumar Javarappa, Mika Kontro, Blassan Plackal Adimuriyil George, Raphaël Itzykson, Markku T Varjosalo, Risto Renkonen, Esko M Kankuri, Paul A. Haynes, Amir Ata Saei, Mohieddin Jafari
This study uses CoPISA and proteomics to analyze venetoclax-azacitidine response in AML cells, identifying adaptive vulnerabilities like NRP2.
bioRxiv · Sep 23, 2026 · PreprintCancer Biology